Form 4 for ABCL AbCellera Biologics Inc.
Accepted 2024-06-24 00:00:00 ET · period of report 2024-06-21 · accession 0001628280-24-029675 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2024-06-24 | 2024-06-21 | ABCL | Lecault Veronique | COO, Dir | M - OptEx | $0.19 | +83.3K | 2.12M | +4% | +$15.8K |
| D | 2024-06-24 | 2024-06-21 | ABCL | Lecault Veronique | COO, Dir | M - OptEx | $0.00 | -83.3K | 3.83M | -2% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Shares | 2024-06-21 | M | A | 83,334 | $0.19 | 2,123,456 | D | — | — | |
| 2 | Derivative | Share option (right to buy) | 2024-06-21 | M | D | 83,334 | $0.00 | 3,829,771 | D | $0.19 · — to 2027-03-23 | 83,334 Common Shares | (F3) The shares subject to such option vest and become exercisable annually in substantially equal installments over a six-year period, with the first tranche vested on November 8, 2017, subject to the Reporting Person's continuous service to the Issuer on each such date. |